{Reference Type}: Case Reports
{Title}: Successful Treatment of Rituximab-Induced Crohn's Disease With Ustekinumab.
{Author}: Li XJ;Fung BM;Kumar R;
{Journal}: ACG Case Rep J
{Volume}: 11
{Issue}: 7
{Year}: 2024 Jul
暂无{DOI}: 10.14309/crj.0000000000001403
{Abstract}: Autoimmune optic papillitis is a rare disorder that causes progressive visual loss, often treated with rituximab (RTX). However, its use is not without risks. Here, we present a 51-year-old man who experienced vision loss because of autoimmune optic papillitis, which was well-controlled with RTX. Four years later, the patient developed abdominal pain and diarrhea and was found to have RTX-induced Crohn's disease (CD). The patient failed treatment with azathioprine, but was subsequently able to achieve clinical and endoscopic remission of his CD with ustekinumab, while continuing RTX therapy for autoimmune optic papillitis. This case report describes the efficacy of the anti-interleukin 12/23 monoclonal antibody in inducing remission of RTX-induced CD.